PMID- 37293155
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230612
IS  - 2156-6976 (Print)
IS  - 2156-6976 (Electronic)
IS  - 2156-6976 (Linking)
VI  - 13
IP  - 5
DP  - 2023
TI  - Ly6D facilitates chemoresistance in laryngeal squamous cell carcinoma through 
      miR-509/beta-catenin signaling pathway.
PG  - 2155-2171
AB  - Chemotherapy resistance is a major limiting factor in the cure of patients with 
      laryngeal squamous cell carcinoma (LSCC). Lymphocyte antigen 6 superfamily member 
      D (Ly6D) is highly expressed in various tumors, but its role and underlying 
      molecular mechanisms in chemoresistance of LSCC cells remains largely unclear. In 
      this study, we reveal that overexpression of Ly6D facilitates LSCC cell 
      chemoresistance, while Ly6D silencing abolishes this phenotype. Moreover, 
      bioinformatics analysis, PCR array, and functional analysis confirmed that 
      activation of the Wnt/beta-catenin pathway contributes to Ly6D-mediated 
      chemoresistance. The genetic and pharmacological inhibition of beta-catenin 
      compromises chemoresistance mediated by Ly6D overexpression. Mechanistically, 
      Ly6D overexpression significantly attenuates the expression of miR-509-5p, 
      thereby unleashing its target gene CTNNB1 to activate Wnt/beta-catenin pathway and 
      ultimately promote chemoresistance. In contrast, Ly6D augmenting 
      beta-catenin-mediated chemoresistance in LSCC cells were reversed by ectopic 
      expression of miR-509-5p. Furthermore, ectopic expression of miR-509-5p markedly 
      repressed the two other targets, MDM2 and FOXM1. Taken together, these data not 
      only reveal the key role of Ly6D/miR-509-5p/beta-catenin in chemotherapy resistance, 
      but also provide a new strategy for the clinical treatment of refractory LSCC.
CI  - AJCR Copyright (c) 2023.
FAU - Wang, Jue
AU  - Wang J
AD  - Department of Prosthodontics, First Hospital of Shanxi Medical University Taiyuan 
      030001, Shanxi, China.
AD  - Department of Otolaryngology, Head & Neck Surgery, First Hospital of Shanxi 
      Medical University Taiyuan 030001, Shanxi, China.
AD  - The Key Scientific and Technological Innovation Platform for Precision Diagnosis 
      and Treatment of Head and Neck Cancer Taiyuan 030001, Shanxi, China.
AD  - Shanxi Key Laboratory of Otorhinolaryngology, Head and Neck Cancer Taiyuan 
      030001, Shanxi, China.
FAU - Sheng, Nanning
AU  - Sheng N
AD  - Department of Otolaryngology, Head & Neck Surgery, First Hospital of Shanxi 
      Medical University Taiyuan 030001, Shanxi, China.
AD  - The Key Scientific and Technological Innovation Platform for Precision Diagnosis 
      and Treatment of Head and Neck Cancer Taiyuan 030001, Shanxi, China.
AD  - Shanxi Key Laboratory of Otorhinolaryngology, Head and Neck Cancer Taiyuan 
      030001, Shanxi, China.
AD  - Faculty of Stomatology, Shanxi Medical University Taiyuan 030001, Shanxi, China.
FAU - Li, Ying
AU  - Li Y
AD  - Department of Prosthodontics, First Hospital of Shanxi Medical University Taiyuan 
      030001, Shanxi, China.
FAU - Fan, Yawei
AU  - Fan Y
AD  - Department of Oral and Maxillofacial Surgery, First Hospital of Shanxi Medical 
      University Taiyuan 030001, Shanxi, China.
FAU - Nan, Xinrong
AU  - Nan X
AD  - Department of Oral and Maxillofacial Surgery, First Hospital of Shanxi Medical 
      University Taiyuan 030001, Shanxi, China.
FAU - Fu, Rong
AU  - Fu R
AD  - School of Basic Medical Sciences, Shanxi Medical University Taiyuan 030001, 
      Shanxi, China.
LA  - eng
PT  - Journal Article
DEP - 20230515
PL  - United States
TA  - Am J Cancer Res
JT  - American journal of cancer research
JID - 101549944
PMC - PMC10244118
OTO - NOTNLM
OT  - Ly6D
OT  - chemoresistance
OT  - laryngeal squamous cell carcinoma
OT  - miR-509
OT  - beta-catenin
COIS- None.
EDAT- 2023/06/09 06:41
MHDA- 2023/06/09 06:42
PMCR- 2023/05/15
CRDT- 2023/06/09 04:30
PHST- 2023/01/30 00:00 [received]
PHST- 2023/04/25 00:00 [accepted]
PHST- 2023/06/09 06:42 [medline]
PHST- 2023/06/09 06:41 [pubmed]
PHST- 2023/06/09 04:30 [entrez]
PHST- 2023/05/15 00:00 [pmc-release]
PST - epublish
SO  - Am J Cancer Res. 2023 May 15;13(5):2155-2171. eCollection 2023.